

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$2.18 Billion in August

保瑞公告 8 月自結合併營收新台幣 21 億 8 仟萬元

Taipei, Taiwan, September 7, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenue for August 2026 reached NT\$2.18 billion, second-highest on record and up 59.22% year-over-year. Cumulative revenue for the year to date totaled NT\$13,979 million, an increase of 6.09%.

台北，台灣，2026 年 9 月 7 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 8 月自結合併營收為新台幣 21 億 8 仟萬元，年對年增加 59.22%，創歷史次高；今年累計營收達新台幣 139.79 億，年增 6.09%。

Bora noted that CDMO orders deferred from July were shipped in August, with solid revenue contributions from its North America based facilities including Canada, injectable site in Maryland, and the biologics site in Rockville. In addition, flagship specialty and brand franchise of Upsher-Smith, 3 dosage forms of Vigabatrin, once again set record-high revenue during the period, signaling improving product mix for pharma sales business. Newly acquired Weider Global Nutrition, held through subsidiary Sunway Biotech, remained steady, though it is consolidating ahead of a stronger September–October retail peak season.

保瑞指出，7 月 CDMO 訂單挪移至 8 月已出貨，加拿大廠、馬里蘭州針劑廠與生物製劑的洛克維爾廠營收貢獻不俗；在全球銷售部分，Upsher-Smith 的專科品牌藥旗艦產品線 Vigabatrin 三個劑型再次創下歷史新高營業額，產品組合持續好轉。子公司晨暉生技新併購的威德表現仍相當穩健，惟在進入九月、十月的零售旺季前將先蹲後跳。

The subsidiary's Board today approved a sale-and-leaseback of the real estate at the Zhongli facility plant II, at a sale price of NT\$850 million. Bora's Taiwan-based CDMO entity, Bora Pharmaceutical Laboratories Inc., will lease the property back from the buyer for 5 years at market rates. Through this transaction, the Group has converted its prior holding and financing costs into market value, not only bringing the disposal proceeds back in a one-time inflow and releasing a disposal gain of approximately NT\$114 million but also shifting the annual leaseback expense onto a highly profitable operating entity, building long-term tax efficiency. This forms part of the Group's ongoing efforts to optimize its asset structure and improve capital efficiency. Under this arrangement, the transaction is expected to generate stable contributions of approximately NT\$16.65 million in net profit and cash inflow every year.

子公司董事會也於今日通過中壢廠二廠的不動產售後租回案，出售價金為新台幣 8.5 億元，保瑞位於台灣的 CDMO 子公司益邦製藥將依市場行情向買方回租五年。透過本次交易，集團將原先之持有及融資成本成功轉換為市場價值，除了讓處分價金一次回流並釋放資產處分利益約新台幣 1.14 億元外，每年回租費用將由具高獲利能力之營運主體承擔，提升長期租稅利益，此為集團持續優化資產結構、提升資金運用效率之一環。在此安排下，預期每年可穩定產生新台幣約 1,665 萬元淨利與現金流入之雙效貢

獻。

Bora Group Chairman Bobby Sheng commented: "2026 is the year Bora shines on the global CDMO stage. Beyond setting record highs in new contract signings and order backlog, we are also gearing up for AI enabled CDMO capability building. By maintaining financial discipline to drive our CDMO-focused technology upgrades, Bora will continue to create shareholder value in the pharmaceutical industry."

對此，保瑞集團董事長盛保熙指出：「2026 是保瑞在國際 CDMO 舞台發光發熱的一年，我們除了創下史上最好的新簽約成績與在手訂單指標，更熱身準備跨入 AI 賦能 CDMO 領域，持續透過財務紀律促進聚焦 CDMO 的技術升級，保瑞將持續在製藥領域創造股東價值。」

About Bora:

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472.TW與BORAY.OTCQX）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdm.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email: Nadiya.Chen@bora-corp.com